Suppr超能文献

基于碳水化合物的化合物的治疗应用:医学进步的甜蜜解决方案。

Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.

作者信息

Lalhmangaihzuala Samson, Vanlaldinpuia Khiangte, Khiangte Vanlalngaihawma, Laldinpuii Zathang, Liana Thanhming, Lalhriatpuia Chhakchhuak, Pachuau Zodinpuia

机构信息

Department of Chemistry, Pachhunga University College, Mizoram University, Aizawl, Mizoram, 796001, India.

Department of Chemistry, Mizoram University, Tanhril, Aizawl, Mizoram, 796004, India.

出版信息

Mol Divers. 2024 Dec;28(6):4553-4579. doi: 10.1007/s11030-024-10810-2. Epub 2024 Mar 30.

Abstract

Carbohydrates, one of the most abundant biomolecules found in nature, have been seen traditionally as a dietary component of foods. Recent findings, however, have unveiled their medicinal potential in the form of carbohydrates-derived drugs. Their remarkable structural diversity, high optical purity, bioavailability, low toxicity and the presence of multiple functional groups have positioned them as a valuable scaffold and an exciting frontier in contemporary therapeutics. At present, more than 170 carbohydrates-based therapeutics have been granted approval by varying regulatory agencies such as United States Food and Drug Administration (FDA), Japan Pharmaceuticals and Medical Devices Agency (PMDA), Chinese National Medical Products Administration (NMPA), and the European Medicines Agency (EMA). This article explores an overview of the fascinating potential and impact of carbohydrate-derived compounds as pharmacological agents and drug delivery vehicles.

摘要

碳水化合物是自然界中最丰富的生物分子之一,传统上被视为食物的饮食成分。然而,最近的研究结果揭示了它们以碳水化合物衍生药物的形式所具有的药用潜力。它们显著的结构多样性、高光学纯度、生物利用度、低毒性以及多个官能团的存在,使其成为当代治疗学中有价值的支架和令人兴奋的前沿领域。目前,已有170多种基于碳水化合物的治疗药物获得了不同监管机构的批准,如美国食品药品监督管理局(FDA)、日本药品和医疗器械管理局(PMDA)、中国国家药品监督管理局(NMPA)以及欧洲药品管理局(EMA)。本文概述了碳水化合物衍生化合物作为药理剂和药物递送载体的迷人潜力和影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验